Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MatriPlax in ARDS
NCT05886985Phase 1Not yet recruiting
- Sponsor
- BioSpring
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MatriPlax in acute respiratory distress syndrome (ARDS) (3 cohorts), sponsored by BioSpring. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 1 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
MatriPlax
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05886985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886985.